(Q33931680)

30 July 2017

title

Presence of interferon regulatory factor-1 in aggressive and nonaggressive histological variants of Basal cell carcinoma specimens (English)

1 reference

30 July 2017

author name string

Nurten Turhan-Haktanir

1

1 reference

30 July 2017

F Husniye Dilek

2

1 reference

30 July 2017

Yavuz Demir

3

1 reference

30 July 2017

Onder Sahin

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Journal of Cutaneous and Aesthetic Surgery

30 July 2017

published in

1 reference

30 July 2017

volume

3

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

34-37

1 reference

Current modalities and new advances in the treatment of basal cell carcinoma

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Aggressive basal cell carcinoma: presentation, pathogenesis, and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Interferon regulatory factor expression in human breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

IRF family of transcription factors as regulators of host defense

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Interferon regulatory factor-1 and -2 expression in human melanoma specimens.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Cytokine induction of interferon regulatory factor-1 in hepatocytes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Cells resistant to interferon-beta respond to interferon-gamma via the Stat1-IRF-1 pathway

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

The effect of topical interferon alpha 2b on actinic keratoses

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Treatment of aggressive basal cell carcinoma with intralesional interferon: Evaluation of efficacy by Mohs surgery

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Guidelines for the management of basal cell carcinoma. British Association of Dermatologists

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2890135

Intralesional interferon therapy for basal cell carcinoma

29 October 2018

1 reference

12 December 2020

Treatment of basal cell carcinoma with intralesional interferon

1 reference

12 December 2020

Treatment of basal cell carcinoma with intralesional interferon alpha-2b

1 reference

12 December 2020

Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.4103/0974-2077.63395

1 reference

30 July 2017

1 reference

30 July 2017

1 reference